{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:15:46Z","timestamp":1785284146339,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-025-04293-4","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T08:20:45Z","timestamp":1755159645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management and safety of same day bilateral intravitreal anti-VEGF injections in a treat-and-extend regimen"],"prefix":"10.1186","volume":"25","author":[{"given":"Christina","family":"Plasencia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Eschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"issue":"22","key":"4293_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199411033311801","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, et al. Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders. N Engl J Med. 1994;331(22):1480\u20137. https:\/\/doi.org\/10.1056\/NEJM199411033311801.","journal-title":"N Engl J Med."},{"issue":"11","key":"4293_CR2","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON: A Multicenter Cohort Study (SEVEN-UP). Ophthalmology. 2013;120(11):2292\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046.","journal-title":"Ophthalmology."},{"issue":"4","key":"4293_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology. 2012;119(4):789\u2013801. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.039.","journal-title":"Ophthalmology."},{"issue":"10","key":"4293_CR4","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","volume":"119","author":"R Varma","year":"2012","unstructured":"Varma R, Bressler NM, Su\u00f1er IJ, et al. Improved Vision-Related Function After Ranibizumab for Macular Edema After Retinal Vein Occlusion: Results From the BRAVO and CRUISE Trials. Ophthalmology. 2012;119(10):2108\u201318. https:\/\/doi.org\/10.1016\/j.ophtha.2012.05.017.","journal-title":"Ophthalmology."},{"issue":"1","key":"4293_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results of the VIEW Studies. Ophthalmology. 2014;121(1):193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011.","journal-title":"Ophthalmology."},{"issue":"11","key":"4293_CR6","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.006.","journal-title":"Ophthalmology."},{"key":"4293_CR7","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2147\/OPTH.S140665","volume":"11","author":"A Pielen","year":"2017","unstructured":"Pielen A, Clark WL, Boyer DS, et al. Integrated results from the COPERNICUS and GALILEO studies. Clin Ophthalmol. 2017;11:1533\u201340. https:\/\/doi.org\/10.2147\/OPTH.S140665.","journal-title":"Clin Ophthalmol"},{"key":"4293_CR8","doi-asserted-by":"publisher","unstructured":"Anderson WJ, Akduman L. Brolucizumab: what\u2019s new and newer about it? Retina-Vitreus. 2020;29(4):287\u201391. https:\/\/doi.org\/10.37845\/RET.VIT.2020.29.52.","DOI":"10.37845\/RET.VIT.2020.29.52"},{"issue":"8","key":"4293_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, et al. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology. 2024;131(8):914\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014.","journal-title":"Ophthalmology."},{"issue":"10326","key":"4293_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6.","journal-title":"Lancet."},{"issue":"8","key":"4293_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, et al. Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials. Ophthalmology. 2024;131(8):950\u201360. https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.029.","journal-title":"Ophthalmology."},{"key":"4293_CR12","unstructured":"Lucentis\u00ae. Compendium.ch - Arzneimittelinformationen f\u00fcr Fachkreise. [cited 2025 April 15]. https:\/\/compendium.ch\/product\/1260028-lucentis-inj-los-1-65-mg-0-165ml\/mpro."},{"key":"4293_CR13","unstructured":"Eylea\u00ae. Compendium.ch - Arzneimittelinformationen f\u00fcr Fachkreise. [cited 2025 April 15]. https:\/\/compendium.ch\/product\/1427198-eylea-inj-los-2-mg-0-05ml-fertspr\/mpro."},{"issue":"2","key":"4293_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","volume":"114","author":"DS Boyer","year":"2007","unstructured":"Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246\u201352. https:\/\/doi.org\/10.1016\/j.ophtha.2006.10.045.","journal-title":"Ophthalmology"},{"key":"4293_CR15","doi-asserted-by":"publisher","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study. Ophthalmology. 116(1):57\u201365.e5. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018.","DOI":"10.1016\/j.ophtha.2008.10.018"},{"key":"4293_CR16","doi-asserted-by":"publisher","unstructured":"Bjerager J, Hajari J, Klefter ON, Subhi Y, Schneider M. Systemic adverse events and all-cause mortality following same-session bilateral intravitreal anti-VEGF injections: a systematic review. Graefes Arch Clin Exp Ophthalmol. 2024. https:\/\/doi.org\/10.1007\/s00417-023-06368-8.","DOI":"10.1007\/s00417-023-06368-8"},{"issue":"10","key":"4293_CR17","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847\u201358.","journal-title":"Retina"},{"issue":"2","key":"4293_CR18","first-page":"e154","volume":"93","author":"C Zehetner","year":"2015","unstructured":"Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, et al. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Oncol. 2015;93(2):e154\u20139.","journal-title":"Acta Oncol."},{"issue":"7","key":"4293_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27(7):787\u201394. https:\/\/doi.org\/10.1038\/eye.2013.107.","journal-title":"Eye"},{"key":"4293_CR20","doi-asserted-by":"publisher","unstructured":"Bjerager J, Hajari J, Klefter ON, Subhi Y, Schneider M. Endophthalmitis following same-day bilateral anti-VEGF injections: a systematic review. Int Ophthalmol. 2024;44(1). https:\/\/doi.org\/10.1007\/s10792-024-02983-4.","DOI":"10.1007\/s10792-024-02983-4"},{"key":"4293_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2018.06.022","volume":"194","author":"DS Borkar","year":"2018","unstructured":"Borkar DS, Obeid A, Su DC, Storey PP, Gao X, Regillo CD, et al. Endophthalmitis rates after bilateral same-day intravitreal anti-vascular endothelial growth factor injections. Am J Ophthalmol. 2018;194:1\u20136.","journal-title":"Am J Ophthalmol."},{"issue":"1","key":"4293_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000499115","volume":"242","author":"VR Juncal","year":"2019","unstructured":"Juncal VR, Francisconi CL, Altomare F, Chow DR, Giavedoni LR, Muni RH, et al. Same-day bilateral intravitreal anti-vascular endothelial growth factor injections: experience of a large Canadian retina center. Ophthalmologica. 2019;242(1):1\u20137.","journal-title":"Ophthalmologica."},{"key":"4293_CR23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/IAE.0000000000000399","volume":"34","author":"RL Avery","year":"2014","unstructured":"Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ET Jr, D\u2019Amico DJ, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34:S1\u201318.","journal-title":"Retina."},{"key":"4293_CR24","doi-asserted-by":"crossref","unstructured":"Nivelle E, Caekelbergh K, Moeremans K, Gerlier L, Drieskens S, Van\u00a0dijck P. Non-interventional study on the burden of illness in diabetic macular edema (DME) in Belgium. Value Health. 2012;15(7):A570.","DOI":"10.1016\/j.jval.2012.08.2055"},{"key":"4293_CR25","doi-asserted-by":"publisher","unstructured":"Milton RC, Clemons TE, Klien R, Seddon JM, Ferris FL. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS): AREDS report no. 19. Ophthalmology. 2005;112(4):533\u2013539.e1. https:\/\/doi.org\/10.1016\/j.ophtha.2004.10.047.","DOI":"10.1016\/j.ophtha.2004.10.047"},{"issue":"6","key":"4293_CR26","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ajo.2010.01.007","volume":"149","author":"IA Barbazetto","year":"2010","unstructured":"Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol. 2010;149(6):939-946.e1. https:\/\/doi.org\/10.1016\/j.ajo.2010.01.007.","journal-title":"Am J Ophthalmol."},{"issue":"4","key":"4293_CR27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ophtha.2014.11.018","volume":"122","author":"MC Peden","year":"2015","unstructured":"Peden MC, Su\u00f1er IJ, Hammer ME, Grizzard WS. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology. 2015;122(4):803\u20138. https:\/\/doi.org\/10.1016\/j.ophtha.2014.11.018.","journal-title":"Ophthalmology"},{"issue":"10","key":"4293_CR28","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjophthalmol-2015-307299","volume":"100","author":"K Hatz","year":"2016","unstructured":"Hatz K, Pr\u00fcnte C. Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100(10):1341\u20135. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307299.","journal-title":"Br J Ophthalmol."},{"issue":"3","key":"4293_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1159\/000514721","volume":"64","author":"H Giannakaki-Zimmermann","year":"2021","unstructured":"Giannakaki-Zimmermann H, Behrndt A, Hoffmann L, Guichard MM, T\u00fcrksever C, Pr\u00fcnte C, et al. Predictors for 2-year functional and morphological outcomes of a treat-and-extend regimen with ranibizumab in patients with diabetic macular edema. Ophthalmic Res. 2021;64(3):465\u201375.","journal-title":"Ophthalmic Res"},{"issue":"1","key":"4293_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000487489","volume":"60","author":"MM Guichard","year":"2018","unstructured":"Guichard MM, Xavier AR, T\u00fcrksever C, Pruente C, Hatz K. Spectral-domain optical coherence tomography-driven treat-and-extend and pro re nata regimen in patients with macular oedema due to retinal vein occlusion: 24-month evaluation and outcome predictors. Ophthalmic Res. 2018;60(1):29\u201337.","journal-title":"Ophthalmic Res"},{"issue":"7","key":"4293_CR31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046\u201350.","journal-title":"Retina."},{"issue":"4","key":"4293_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000486145","volume":"239","author":"A Grzybowski","year":"2018","unstructured":"Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, et al. 2018 update on intravitreal injections: euretina expert consensus recommendations. Ophthalmologica. 2018;239(4):181\u201393.","journal-title":"Ophthalmologica."},{"key":"4293_CR33","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.3509134","author":"The pandas development team","year":"2020","unstructured":"The pandas development team. pandas-dev\/pandas: Pandas. Zenodo. 2020. https:\/\/doi.org\/10.5281\/zenodo.3509134.","journal-title":"Zenodo"},{"key":"4293_CR34","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.15375714","author":"The Matplotlib Development Team","year":"2025","unstructured":"The Matplotlib Development Team. Matplotlib: Visualization with Python. Zenodo. 2025. https:\/\/doi.org\/10.5281\/zenodo.15375714.","journal-title":"Zenodo"},{"key":"4293_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.softx.2020.100508","volume":"11","author":"J Eschle","year":"2020","unstructured":"Eschle J, Puig Navarro A, Silva Coutinho R, Serra N. Zfit: scalable pythonic fitting. SoftwareX. 2020;11: 100508. https:\/\/doi.org\/10.1016\/j.softx.2020.100508.","journal-title":"SoftwareX"},{"key":"4293_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy 1.0: fundamental algorithms for scientific computing in python. Nat Methods. 2020;17:261\u201372. https:\/\/doi.org\/10.1038\/s41592-019-0686-2.","journal-title":"Nat Methods"},{"key":"4293_CR37","doi-asserted-by":"publisher","unstructured":"Haynes W. In: Dubitzky W, Wolkenhauer O, Cho KH, Yokota H, editors. Bonferroni correction. New York: Springer New York; 2013. p. 154. https:\/\/doi.org\/10.1007\/978-1-4419-9863-7_1213.","DOI":"10.1007\/978-1-4419-9863-7_1213"},{"issue":"9","key":"4293_CR38","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1097\/IAE.0b013e3181b32d27","volume":"29","author":"LH Lima","year":"2009","unstructured":"Lima LH, Zweifel SA, Engelbert M, Sorenson JA, Slakter JS, Cooney MJ, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina. 2009;29(9):1213\u20137.","journal-title":"Retina."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04293-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04293-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04293-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:21:49Z","timestamp":1757456509000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04293-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4293"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04293-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All included patients gave general written informed consent or were included in the assumption of their consent to avoid attrition-bias if obtaining general consent was disproportionate or impossible, as those patients were no longer being treated at our clinic at the time of the analysis, as approved by the local ethics committee (Kantonale Ethics Committee Northwestern Switzerland, EKNZ, EKNZ No 2019\u201300752). Thereby agreeing for their use of health-related personal data for research purposes. This study was conducted according to the Declaration of Helsinki of the World Medical Association in accordance with the Good Clinical Practice Guidelines of the International Conference on Harmonisation (ICH).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KH: Advisory board participant and lecturer for Apellis, Bayer, Roche, Abbvie\/Allergan, Novartis; contract research and\/or grant support for Bayer, Roche, Abbvie\/Allergan, Novartis. No financial disclosures by all other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"459"}}